Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement.

Trial Profile

Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Edoxaban (Primary) ; Acenocoumarol; Aspirin; Clopidogrel; Fluindione; Phenprocoumon; Prasugrel; Ticagrelor; Warfarin
  • Indications Embolism
  • Focus Therapeutic Use
  • Acronyms ENTRUST-AF-PCI
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 06 Oct 2017 Planned End Date changed from 1 Feb 2019 to 1 Mar 2018.
    • 06 Oct 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Mar 2018.
    • 06 Mar 2017 According to the Daiichi Sankyo Company's media release, company today announced that the first patient has been enrolled in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top